In vitro effects of indinavir or saquinavir on cell survival and viral replication in fresh peripheral blood mononuclear cells taken from HIV-1 patients under HAART
| Patient no. . | CD4 cells (μL−1) . | Cell survival-enhancing (EC)3-150 . | Viral (p24) inhibition (EC)3-151 . | ||
|---|---|---|---|---|---|
| Indinavir (nmol/L) . | Saquinavir (nmol/L) . | Indinavir (nmol/L) . | Saquinavir (nmol/L) . | ||
| I. Virologic responders | |||||
| 6 | 88 | 1-1000 | 1-1000 | 38 (±13) | 27 (±8) |
| 28 | 105 | 3-30 | 3-30 | NA3-152 | NA |
| 32 | 262 | 1-1000 | 1-1000 | NA | NA |
| 51 | 493 | 1-100 | 1-100 | NA | NA |
| 55 | 645 | 10-100 | 10-100 | NA | NA |
| II. Virologic transient responders | |||||
| 62 | 108 | 1-1000 | 1-1000 | 453 (±98) | 211 (±76) |
| 68 | 250 | 1-1000 | 1-1000 | NA | NA |
| 74 | 306 | 1-100 | 1-100 | 214 (±72) | 169 (±54) |
| 80 | 523 | 1-100 | 1-100 | 37 (±12) | 22 (±5) |
| 82 | 649 | 1-30 | 1-30 | 51 (±22) | 29 (±8) |
| III. Virologic non responders | |||||
| 83 | 69 | 1-1000 | 1-1000 | 39 (±15) | 25 (±7) |
| 92 | 148 | 1-1000 | 1-1000 | 42 (±13) | 31 (±10) |
| 95 | 347 | 1-100 | 1-100 | 343 (±84) | 179 (±68) |
| 96 | 567 | 1-100 | 1-100 | 45 (±17) | 28 (±9) |
| 97 | 764 | 10-100 | 10-100 | 64 (±21) | 35 (±11) |
| Patient no. . | CD4 cells (μL−1) . | Cell survival-enhancing (EC)3-150 . | Viral (p24) inhibition (EC)3-151 . | ||
|---|---|---|---|---|---|
| Indinavir (nmol/L) . | Saquinavir (nmol/L) . | Indinavir (nmol/L) . | Saquinavir (nmol/L) . | ||
| I. Virologic responders | |||||
| 6 | 88 | 1-1000 | 1-1000 | 38 (±13) | 27 (±8) |
| 28 | 105 | 3-30 | 3-30 | NA3-152 | NA |
| 32 | 262 | 1-1000 | 1-1000 | NA | NA |
| 51 | 493 | 1-100 | 1-100 | NA | NA |
| 55 | 645 | 10-100 | 10-100 | NA | NA |
| II. Virologic transient responders | |||||
| 62 | 108 | 1-1000 | 1-1000 | 453 (±98) | 211 (±76) |
| 68 | 250 | 1-1000 | 1-1000 | NA | NA |
| 74 | 306 | 1-100 | 1-100 | 214 (±72) | 169 (±54) |
| 80 | 523 | 1-100 | 1-100 | 37 (±12) | 22 (±5) |
| 82 | 649 | 1-30 | 1-30 | 51 (±22) | 29 (±8) |
| III. Virologic non responders | |||||
| 83 | 69 | 1-1000 | 1-1000 | 39 (±15) | 25 (±7) |
| 92 | 148 | 1-1000 | 1-1000 | 42 (±13) | 31 (±10) |
| 95 | 347 | 1-100 | 1-100 | 343 (±84) | 179 (±68) |
| 96 | 567 | 1-100 | 1-100 | 45 (±17) | 28 (±9) |
| 97 | 764 | 10-100 | 10-100 | 64 (±21) | 35 (±11) |
HIV-1, human immunodeficiency virus type 1; HAART, highly active antiretroviral therapy; EC, effective concentrations.
Effective concentrations for cell survival enhancement were defined as drug concentration ranges that resulted in a net gain 50 × 106 viable cells, compared with the survival of patients' PBMCs in the absence of indinavir or saquinavir.
Effective concentrations for viral inhibition were determined as the mean (±SD) drug concentrations showing 90% suppression of HIV-1 p24 production in culture supernatants, compared with patients' PBMC cultures in the absence of indinavir or saquinavir.
Due to a negative result for p24 ELISA in the supernatants of the 16-day culture.